Abstract
A new study has advanced our understanding of iron management in chronic kidney disease (CKD) by comparing oral iron to high-dose and low-dose intravenous ferric carboxymaltose (FCM) in patients with predialysis CKD. Intravenous FCM treatment to achieve a higher serum ferritin target improved patient haemoglobin levels and reduced initiation of other anaemia treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
